Abstract: The efficacy of conventional chemotherapy for gastric cancer is extremely limited because of its relatively low chemo-sensitivity and obvious heterogeneity.Molecular phenotype-directed target therapy is important for the improvement of the efficacy of conventional chemotherapy in treating advanced gastric cancer.Trastuzumab has been confirmed to have a survival benefit when added to chemotherapy for HER-2 positive gastric cancer.Ramucirumab can increase the survival of gastric cancer patients as second line treatment compared with a placebo.The anti-c-MET monoclonal antibody Rilotumumab indicates promising results in phaseⅡtrial.However, most of the targeting drugs in gastric cancer clinical trials have failed.Therefore, further efforts are required to explore critical targeted genes and effective agents.